ArticleNature communications2026
Functional protein design and enhancement with ontology reinforcement iteration.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discrepancy between computational modeling and experimental performance remains a major challenge in protein engineering. We present ORI (Ontology Reinforcement Iteration), a scalable framework integrating ontology-conditioned decoding with reinforcement learning from experimental feedback (RLWF). ORI leverages structured ontologies as semantic prompts to impose multi-level constraints, enabling controllable and interpretable protein generation. A closed-loop iterative workflow-comprising generation, experimental measurement, and model updating-enables continuous optimization under real-world objectives. We demonstrate ORI's practical applicability through diverse tasks, including enzymatic activity optimization, thermal stability enhancement, and multifunctional protein engineering. Using this framework, we engineer variants with substantial improvements over natural baselines, such as a lysozyme with 100-fold higher activity, a chitinase stable at 85 °C, and dual-function enzymes exhibiting both lysozyme and chitinase activities. These results establish ORI as a robust technical platform for efficient, multi-objective protein engineering in real-world experimental settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.